Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
LUNG Stock Chart & Stats
$2.52
-$0.17(-2.57%)
At close: 4:00 PM EST
$2.52
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.31 - $9.37
Previous CloseN/A
Volume95.69K
Average Volume (3M)308.20K
Market Cap
$104.77M
Enterprise Value$77.06M
Total Cash (Recent Filing)$76.55M
Total Debt (Recent Filing)$56.56M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Feb 25, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding41,247,032
10 Day Avg. Volume245,979
30 Day Avg. Volume308,202
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)3.09
Price to Sales (P/S)3.17
P/FCF Ratio-8.05
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit1.15
Enterprise Value/Ebitda-1.42
Forecast
1Y Price Target
$4.10Price Target Upside62.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformancePulmonx announced preliminary Q3 revenue of $21.5M, which exceeded both the analyst's estimate and the consensus, indicating strong financial performance.
Management And LeadershipThe company is now in the hands of experienced operators that know the business and are highly incentivized to fix the issues at hand.
Strategic PlanningThe new management team is expected to outline a strategy to return Pulmonx to a high-growth company, which is viewed positively by analysts.
Bears Say
Guidance AdjustmentGuidance cut as new management wants to set achievable numbers as they get reoriented with the business.
Sales Performance UncertaintyIt is too early to tell if the underperforming sales territories are a people or structural problem.
Pulmonx News
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $1.31 and its highest was $9.37 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is $104.77M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Feb 25, 2026 which is in 68 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Nov 12, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.082.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.4.
How many shares outstanding does Pulmonx have?
Pulmonx has 41,247,032 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went down -18.878%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.10 (62.70% Upside)
$4.10 (62.70% Upside)
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.30%
12-Months-Change
Fundamentals
Return on Equity
-73.73%
Trailing 12-Months
Asset Growth
-14.74%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
LUNG Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with some positive developments in international growth and gross margin improvement, but ongoing challenges in U.S. growth, rising expenses, persistent net loss, and decreasing cash reserves. The focus on execution and profitability suggests attempts to address these issues, but immediate growth strategies remain uncertain.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$4.10
▲(62.70% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
6.78% Insiders
23.82% Mutual Funds
25.25% Other Institutional Investors
28.96% Public Companies and
Individual Investors